Russell Scharf
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Russell Scharf has a total of 9 co-authors. Here are the top co-authors by number of shared publications:
- Amit Verma
Albert Einstein College of Medicine
5 shared publications - Goichi Tatsumi
Department of Hematology and Oncology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
5 shared publications - Justin C. Wheat
Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY 10065, USA
5 shared publications - Rajni Kumari
Albert Einstein College of Medicine 1 Department of Cell Biology Bronx, New York
5 shared publications - Samuel J. Taylor
School of Pathology and Laboratory Medicine, University of Western Australia, Crawley, Western Australia, Australia
5 shared publications - Shuting Li
Institute of Neuroscience, State Key Laboratory of Neuroscience, CAS Center for Excellence in Brain Science and Intelligence Technology, Chinese Academy of Sciences
5 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Data from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance.Significance:This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessData from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance.Significance:This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S6 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Table 1: Key Reagents & Resources. Table 2: WES. Table 3: Primers and sgRNAs. Table 4: GSEA. Table 5: SmFISH probes. Table 6: Patient samples.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S6 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Table 1: Key Reagents & Resources. Table 2: WES. Table 3: Primers and sgRNAs. Table 4: GSEA. Table 5: SmFISH probes. Table 6: Patient samples.
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Key Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Key Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessKey Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Key Resources Table S1 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
- Open Access
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S9 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Figure S1. The effects of short-term AraC treatment on RNA transcription dynamics and AraC resistance acquisition. Figure S2.Absence of genetic clonal selection in rapid AraC resistance development. Figure S3. Suppression of RNA induction interferes with the acquisition of AraC resistance in NB4 and MOLM14. Figure S4. Transcriptomic profiling identifies key role of AraC-rapid response TFs (ARRTFs) in acquisition of drug resistance. Figure S5. Not all hematopoiesis-related TFs are transcriptionally activated following AraC treatment. Figure S6. Transcription dynamics after AraC treatment inNB4. Figure S7. Modest changes in chromatin accessibility (detected by ATACseq) during the development of rapidAraC drug resistance. Figure S8. Flow cytometry gating strategy for analyzing RNA dynamics in hematopoietic stem and progenitor cells (HSPCs) of AMLpatient samples. Figure S9. Evaluation of cell proliferation of control and TF-KO subclones in steady state.
- 1 July 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S9 from Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Figure S1. The effects of short-term AraC treatment on RNA transcription dynamics and AraC resistance acquisition. Figure S2.Absence of genetic clonal selection in rapid AraC resistance development. Figure S3. Suppression of RNA induction interferes with the acquisition of AraC resistance in NB4 and MOLM14. Figure S4. Transcriptomic profiling identifies key role of AraC-rapid response TFs (ARRTFs) in acquisition of drug resistance. Figure S5. Not all hematopoiesis-related TFs are transcriptionally activated following AraC treatment. Figure S6. Transcription dynamics after AraC treatment inNB4. Figure S7. Modest changes in chromatin accessibility (detected by ATACseq) during the development of rapidAraC drug resistance. Figure S8. Flow cytometry gating strategy for analyzing RNA dynamics in hematopoietic stem and progenitor cells (HSPCs) of AMLpatient samples. Figure S9. Evaluation of cell proliferation of control and TF-KO subclones in steady state.
- Open Access
- 18 May 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (4) , 624-641
Rapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance. Significance: This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.
- 18 May 2026
- Published by American Association for Cancer Research (AACR) in Blood Cancer Discovery
- Vol. 7 (4) , 624-641
Open AccessRapid Transcription Dynamics Confers Cytarabine Resistance in Acute Myeloid Leukemia
Chemotherapy resistance remains a critical challenge in the treatment of patients with cancer, including acute myeloid leukemia (AML). Although genetic alterations can contribute to resistance, the role of rapid-adaptive nongenetic mechanisms, particularly transcription dynamics, remains poorly understood. In this article, we demonstrate that short-term treatment of AML cells with the widely used chemotherapeutic cytarabine (AraC) leads to the rapid emergence of a cell population with significant RNA induction and increased AraC resistance in cell lines and primary patient samples. Mechanistically, transcriptomic and targeted high-resolution analysis of transcription dynamics using single-molecule RNA FISH revealed rapid induction of transcriptional dynamics and upregulation of key transcription factors (TF)—which we term “AraC rapid response TFs.” Functionally, short-term pre- and cotreatment with RNA transcription inhibitors suppressed chemotherapy-induced RNA induction and prevented resistance acquisition in vitro and in vivo. Furthermore, CRISPR-mediated suppression of TFs PU.1 and GATA1 significantly attenuated AraC resistance. Our findings reveal a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance. Significance: This study reveals a role of rapid-adaptive transcriptional dynamics in AML chemotherapy resistance, highlighting master TFs as key regulators. These insights offer a pharmacologically accessible approach to potentially alleviate the major clinical problem of chemotherapy resistance.